GH Research (GHRS) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
GH Research (GHRS) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 60.2% versus a loss of 51.1%. Over five years, GHRS leads with a +24.2% price change compared with -80.7% for RARE. Ultragenyx Pharmaceutical is the larger company by market cap ($1.53 billion vs $1.45 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GHRS | RARE |
|---|---|---|
| Share price | $21.11 | $15.48 |
| Market cap | $1.45B | $1.53B |
| 1-day change | +3.23% | +1.24% |
| YTD return | +66.22% | -32.70% |
| 1-year return | +60.17% | -51.11% |
| 5-year return | +24.18% | -80.65% |
| Forward P/E | — | 22.87 |
| EPS (TTM) | $-0.99 | $-5.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $673.00M |
| Revenue growth (YoY) | — | +20.18% |
| Net income (latest FY) | $-48.26M | $-575.00M |
| Operating margin | — | -79.49% |
| Net margin | — | -85.44% |
| 52-week high | $31.44 | $39.89 |
| 52-week low | $12.04 | $12.73 |
| Distance from 52-week high | -32.85% | -61.19% |
| Analyst consensus | none | buy |
| Avg. price target upside | +103.17% | +73.06% |
| Average volume | 294.29K | 3.90M |
| Shares outstanding | 68.64M | 98.59M |
| Employees | 73 | 1,371 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GHRS has outperformed RARE by 111.3 percentage points over the past year.
- The two companies sit in different sectors: GH Research in Health Care and Ultragenyx Pharmaceutical in Healthcare.
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Healthcare · Biotechnology · 1,371 employees
GHRS vs RARE FAQ
Which is bigger, GH Research or Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.53B compared with $1.45B for GH Research (GHRS).
Which stock has performed better over the past year, GHRS or RARE?
GHRS returned +60.17% over the past 12 months, compared with -51.11% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are GH Research and Ultragenyx Pharmaceutical in the same industry?
No. GH Research is in the Health Care sector, while Ultragenyx Pharmaceutical is in Healthcare.